Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly 1Q08 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Lilly 1Q08

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Lilly 

1Q Revenues: $4.8 billion (+14%)

1Q Earnings: $1.1 billion (+109%)

Comments: Alimta, Byetta, Cialis, Cymbalta, Forteo, Strattera, Symbyax, Xigris and Yentreve collectively grew 33% to $1.7 billion, and accounted for 35% of total sales. Cymbalta sales were $605.1 million (+37%). Cialis sales were up 74% to $336.9 million. Alimta sales were $247.2 million (+32%). Zyprexa sales were $1.1 billion (+1%). R&D expenses were  $877.1 million (+5%). In the quarter, the company terminated development of its AIR Insulin program with partner Alkermes. The FDA accepted and gave priority review status to the company’s NDA for prasugrel as a treatment for patients with acute coronary syndrome being managed with percutaneous coronary intervention. 1Q07 earnings were impacted by in-process R&D expenses associated with the ICOS acquisition.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters